Pivotal Trials

Study Finds FDA Pivotal Trials Rarely Reflect U.S. Diversity as Black and Hispanic Enrollment Falls

The peer-reviewed analysis links site selection incentives to under-sampling of genetic diversity that risks missed safety and efficacy signals.